Economy & Bankingv12 · 11 versions
India's Pharmaceutical Sector
India's pharmaceutical industry is the world's third largest by volume and its biggest supplier of generic medicines, yet for many critical ingredients it still leans on China. It is in the news because the Centre has approved a cap of 30 percent of MRP on trade margins for cancer medicines outside the price-control list, and the Health Ministry has proposed that retailers, wholesalers and distributors, like manufacturers, need Central sanction before advertising prescription drugs.
Last updated 9 October 20268 min read
Latest update
Adds the 30 percent-of-MRP cap on cancer-drug trade margins and the draft curb on prescription-drug advertising by sellers; a new section explains NPPA, the DPCO and trade margins.
- PRIP scheme
- Department of Pharmaceuticals
- Biopharma SHAKTI
- MedTech innovation
- pharmaceutical research
- bulk drugs
- Anupriya Patel
- pharmaceuticals
- Drugs Rules 1945
- stem cell therapy
- biosimilars
- CDSCO
- Indian Pharmacopoeia Commission
- PRIP
- National Formulary of India
- PvPI
- pharmacovigilance
- Biovigilance Programme of India
- PLI Bulk Drugs
- PLI Pharmaceuticals
- Penicillin G
- potassium clavulanate
- Kakinada SEZ
- sulfadiazine
- atorvastatin
- para-amino phenol
- Srikakulam
- Nawanshahr
- PRIP New Discovery track
- Section 232
- specialty drugs
- pharmaceutical sector
- PLI bulk drugs
- NPPA
- DPCO 2013
- trade margin
- anti-cancer drugs
- Schedule H
- drug advertising
- price control
Read the full living note — free
The complete note in both exam lenses (UPSC analytical / fact capsule), its full version history, and “what changed since you last read” — plus tonight's quiz.
Open in CA·WikiAI-assisted, human-reviewed · sourced from PIB, RBI & ministries · editorial policy
More living notes in Economy & Banking
- SEBI Regulatory Actions 2026Opened SEBI's 2026 decision log with its exam core and the 7 October circular making a six-level, colour-coded Credit Risk-o-Meter compulsory for debt securities.
- New GDP Series (Base Year 2022-23)Adds the NSO's 9 October draft guideline for States to compile expenditure-side GSDP on the 2022-23 base; no State yet estimates private consumption.
- GST 2.0 — The Two-Slab ReformAdds the 57th GST Council's recommendations — arrest powers dropped, prosecution threshold to ₹5 crore, ₹10,000 notice floor, faster refunds — and trims the note to its exam core.
- India's Maritime & Shipping ReformsLogs the third Sagarmanthan dialogue (shipping ministry with ORF, 7 October 2026) and the India-EU Green Shipping Corridor coalition launched there; older log entries compressed.
- India's Foreign Trade - FY 2026-27Adds India's place among 15 economies backing a USTR-issued statement on structural excess capacity, and Goyal's 8 October reaffirmation of the US$ 1 trillion export goal.
- India's Balance of Payments AccountUpdates foreign exchange reserves to US$734.6 billion on 2 October 2026, down from the US$785.7 billion record of 4 September.